MRI evaluation of the basal ganglia size and iron content in patients with Parkinson's disease

AbstractObjectiveTo evaluate by MRI the area size and the degree of iron accumulation in basal ganglia nuclei that are implicated in the pathogenesis of Parkinson's disease (PD).Methods40 patients with idiopathic PD and 40 controls were examined on a 1. 5 Tesla MR imager, using a multiecho SE sequence 2000/20, 40, 60, 80, 100, 120, 140, 160 (TR/TE). The T2 relaxation time (T2) and the area of substantia nigra zona compacta (SNc), substantia nigra zona reticulata (SNr), putamen (Pu), globus pallidus external (GPe), globus pallidus internal (GPi), caudate nucleus (CN), locus coeruleus (LC) and subthalamic nucleus (STN) were assessed.ResultsThe T2 of SNc (76. 8 ± 6. 0) was lower and of Pu (79.5 ± 6.0) and GPe (69.5 ± 7.0) was higher in patients than in controls (78.6 ± 3.8, 77.4 ± 3.9 and 67.3 ± 5.7, respectively), p < 0.05. The area of CN (125.9 ± 20.2) and Pu (201.5 ± 48.7) was higher in patients than in controls (110.7 ± 21.5 and 180.1 ± 41.1, respectively), p < 0.05. A more pronounced decrease in the T2 of SNc (73.6 ± 8.9) was observed when the more affected side of patients was evaluated separately. In patients with disease duration > 5 years the T2 of STN (71.5 ± 6.3) was lower and the area of Pu was higher (215.3 ± 54.9) compared with those with disease duration ≤ 5 years (75.8 ± 10.9 and 190.9 ± 41.0 respectively), p < 0.05.ConclusionsThese findings suggest that dysfunction of the basal ganglia circuitry in PD may affect iron content not only in SNc but in STN, Pu and GPe as well. Compensatory sprouting of the remaining dopaminergic fibers could account for the increased area of the CN and Pu.

[1]  Wolfhard Semmler,et al.  Multiexponential Proton Spin‐Spin Relaxation in MR Imaging of Human Brain Tumors , 1989, Journal of computer assisted tomography.

[2]  R. Brooks,et al.  T1 and T2 in the brain of healthy subjects, patients with Parkinson disease, and patients with multiple system atrophy: relation to iron content. , 1999, Radiology.

[3]  R. A. Knight,et al.  ASSESSMENT OF RELATIVE BRAIN IRON CONCENTRATIONS USING T-2-WEIGHTED AND T-2(ASTERISK)-WEIGHTED MRI AT 3-TESLA , 1994 .

[4]  F. Ye,et al.  Basal ganglia iron content in Parkinson's disease measured with magnetic resonance , 1996, Movement disorders : official journal of the Movement Disorder Society.

[5]  M. Skalej,et al.  Magnetic resonance imaging–based volumetry differentiates idiopathic Parkinson's syndrome from multiple system atrophy and progressive supranuclear palsy , 1999, Annals of neurology.

[6]  C D Marsden,et al.  Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia. , 1991, Brain : a journal of neurology.

[7]  A. Parent,et al.  Dopaminergic innervation of human basal ganglia , 2000, Journal of Chemical Neuroanatomy.

[8]  P D Griffiths,et al.  Brain iron deposition in Parkinson's disease imaged using the PRIME magnetic resonance sequence. , 2000, Brain : a journal of neurology.

[9]  K. Earle Studies on Parkinson's disease including x-ray fluorescent spectroscopy of formalin fixed brain tissue. , 1968, Journal of neuropathology and experimental neurology.

[10]  G E Santyr,et al.  Magnetization transfer effects in multislice MR imaging. , 1993, Magnetic resonance imaging.

[11]  G. Bartzokis,et al.  In vivo MR evaluation of age-related increases in brain iron. , 1994, AJNR. American journal of neuroradiology.

[12]  P. Boesiger,et al.  T2 relaxation time in patients with Parkinson's disease , 1993, Neurology.

[13]  R M Henkelman,et al.  MR of human postmortem brain tissue: correlative study between T2 and assays of iron and ferritin in Parkinson and Huntington disease. , 1993, AJNR. American journal of neuroradiology.

[14]  K. Mewes,et al.  The subthalamic nucleus in Parkinson's disease: somatotopic organization and physiological characteristics. , 2001, Brain : a journal of neurology.

[15]  P Riederer,et al.  Selective Increase of Iron in Substantia Nigra Zona Compacta of Parkinsonian Brains , 1991, Journal of neurochemistry.

[16]  R. Switzer,et al.  The regional distribution and cellular localization of iron in the rat brain , 1984, Neuroscience.

[17]  D. Calne The free radical hypothesis in idiopathic parkinsonism: Evidence against it , 1992, Annals of neurology.

[18]  G. Percheron,et al.  Topographical and cytological localization of iron in rat and monkey brains , 1981, Brain Research.

[19]  Joannam . Hill Iron concentration reduced in ventral pallidum, globus pallidus, and substantia nigra by GABA-transaminase inhibitor, gamma-vinyl GABA , 1985, Brain Research.

[20]  P. Riederer,et al.  Biochemical fundamentals of Parkinson's disease. , 1988, The Mount Sinai journal of medicine, New York.

[21]  F A Jolesz,et al.  Brain hemorrhage: evaluation with fast spin-echo and conventional dual spin-echo images. , 1992, Radiology.

[22]  R I Grossman,et al.  Magnetic resonance imaging in Parkinson's disease and parkinsonian syndromes , 1989, Neurology.

[23]  A. Lees,et al.  Parkinson's Disease Society Brain Bank, London: overview and research. , 1993, Journal of neural transmission. Supplementum.

[24]  I. McKeith,et al.  MRI Study of Caudate Nucleus Volume in Parkinson’s Disease with and without Dementia with Lewy Bodies and Alzheimer’s Disease , 2003, Dementia and Geriatric Cognitive Disorders.

[25]  P. Boesiger,et al.  Age distribution and iron dependency of the T2 relaxation time in the globus pallidus and putamen , 2004, Neuroradiology.

[26]  K. Jellinger,et al.  Pathology of Parkinson's disease. Changes other than the nigrostriatal pathway. , 1991, Molecular and chemical neuropathology.

[27]  K. Jellinger,et al.  Brain iron and ferritin in Parkinson's and Alzheimer's diseases , 1990, Journal of neural transmission. Parkinson's disease and dementia section.

[28]  G. Reynolds,et al.  Increased iron (III) and total iron content in post mortem substantia nigra of parkinsonian brain , 2005, Journal of Neural Transmission.

[29]  P. Ryvlin,et al.  Magnetic resonance imaging evidence of decreased putamenal iron content in idiopathic Parkinson's disease. , 1995, Archives of neurology.

[30]  P. Riederer,et al.  Altered Brain Metabolism of Iron as a Cause of Neurodegenerative Diseases? , 1994, Journal of neurochemistry.

[31]  R. Ordidge,et al.  Increased iron‐related MRI contrast in the substantia nigra in Parkinson's disease , 1995, Neurology.

[32]  P Z Marmarelis,et al.  MRI evaluation of brain iron in earlier- and later-onset Parkinson's disease and normal subjects. , 1999, Magnetic resonance imaging.

[33]  R. Krüger,et al.  Genetic analysis of immunomodulating factors in sporadic Parkinson's disease , 2000, Journal of Neural Transmission.

[34]  S H Lisanby,et al.  Diminished subcortical nuclei volumes in Parkinson's disease by MR imaging. , 1993, Journal of neural transmission. Supplementum.

[35]  C. Marsden,et al.  Increased Nigral Iron Content and Alterations in Other Metal Ions Occurring in Brain in Parkinson's Disease , 1989, Journal of neurochemistry.

[36]  O. Hassani,et al.  Re-evaluation of the functional anatomy of the basal ganglia in normal and Parkinsonian states , 1997, Neuroscience.

[37]  C. Marsden,et al.  Alterations in levels of iron, ferritin, and other trace metals in neurodegenerative diseases affecting the basal ganglia , 1992 .

[38]  Yoshiharu Tamakawa,et al.  The substantia nigra in Parkinson disease: proton density-weighted spin-echo and fast short inversion time inversion-recovery MR findings. , 2002, AJNR. American journal of neuroradiology.

[39]  Peter Riederer,et al.  Transition Metals, Ferritin, Glutathione, and Ascorbic Acid in Parkinsonian Brains , 1989, Journal of neurochemistry.

[40]  B. Snow,et al.  Criteria for diagnosing Parkinson's disease , 1992, Annals of neurology.

[41]  C. Marsden,et al.  α‐tocopherol levels in brain are not altered in Parkinson's disease , 1992 .

[42]  R A Brooks,et al.  Role of iron and ferritin in MR imaging of the brain: a study in primates at different field strengths. , 1990, Radiology.

[43]  S. Fahn Description of Parkinson's Disease as a Clinical Syndrome , 2003, Annals of the New York Academy of Sciences.